Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2013, Vol. 33 Issue (3): 15-20    DOI:
    
Bioactivity of the Escherichia coli-derived Norovirus P Particles and Its Shape Under TEM
YANG Gui-hua, CHEN Lu-lu, WANG Xiao-lei, LI Shan-shuang, ZHAO Ling-xia
Plant Biotechnology Research Center, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai 200240, China
Download: HTML   PDF(829KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  Human noroviruses(NVs)are primary causes for epidemic nonbacterial gastroenteritis in the world, and high-risk for young children ,elderly peoples and crowd in public location. Currently, usage of the vaccine is a major strategy to prevent infection of NVs and outbreak of acute gastroenteritis in clinic. In order to develop a new vaccine, a PGENE(1 002bp), which encoding P particle of the NVs capsid protein(strain VA387) was designed and synthesized according to tomato codon usage bias, and a DNA sequences encoding 6×His-tag was placed at 5' end of the PGENE for easy to purify the recombinant P particle. Subsequently, the prokaryotic expression vector of the pET32a-PGENE was created and introduced into strain BL21 (Escherichia coli). The BL21 cells harboring pET32a-PGENE were induced by IPTG (isopropyl β-D-1-thiogalactopyranoside) in 1mmol/L final concentration to express the recombinant P particles at 16 ℃. And then, the recombinant P particles were purified by Ni-NTA resin and confirmed by western blotting technique.The E.coli-derived P protein was successfully assembled into global shape and found under TEM (transmission electron microscopy). The antiserum which is from the immunized BALB/c mice using P protein can be specifically binding to the P particles. These results will lay a foundation to produce oral plant vaccine using tomato fruits.

Key wordsNoroviruse      P particles      Subunit vaccine     
Received: 12 November 2012      Published: 25 March 2013
ZTFLH:  Q78  
Cite this article:

YANG Gui-hua, CHEN Lu-lu, WANG Xiao-lei, LI Shan-shuang, ZHAO Ling-xia. Bioactivity of the Escherichia coli-derived Norovirus P Particles and Its Shape Under TEM. China Biotechnology, 2013, 33(3): 15-20.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2013/V33/I3/15

[1] Duizer E, Schwab K J, Neill F H, et al. Laboratory efforts to cultivate noroviruses. J Gen Virol, 2004, 85: 79-87.
[2] Herbst-Kralovetz M, Mason H S, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev Vaccines. 2010, 9(3): 299-307.
[3] Parra G I, Bok K, Taylor R, et al. Immunogenicity and specificity of norovirus consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine, 2012, 30: 3580-3586.
[4] Santi L, Batchelor L, Huang Z, et al. An efficient plant viral expression system generating orally immunogenic norwalk virus-like particles. Vaccine, 2008, 26(15): 1846-1854.
[5] Green K Y, Ando T, Balayan M S, et al. Taxonomy of the caliciviruses. J Infect Dis, 2000, 181: S322-330.
[6] Glass R I, Parashar U D, Estes M K. Norovirus gastroenteritis. N Engl J Med, 2009, 361(18):1776-1785.
[7] Nayak M K., Balasubramanian G, Sahoo G C, et al. Detection of a novel intergenogroup recombinant norovirus from Kolkata, India. Virology, 2008, 377(1): 117-123.
[8] Fukuda S, Sasaki Y, Takao S, et al. Recombinant norovirus implicated in gastroenteritis outbreaks in Hiroshima Prefecture, Japan. J Med Virol, 2008, 80(5): 921-928.
[9] Hutson A M, Atmar R L, Graham D Y, et al. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis, 2002, 185(9): 1335-1337.
[10] Murray E E, Lotzer J, Eberle M. Codon usage in plant genes. Nucl Acids Res, 1989, 17(2): 477-498.
[11] Cao S, Lou Z Y, Tan M, et al. Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol, 2007, 81(11): 5949-5957.
[12] Chen Y, Wang A, Zhao L, et al. Expression of thymosin α1 concatemer in transgenic tomato (Solanum lycopersicum) fruits. Biotechnol Appl Bioc, 2009, 52(4): 303-312.
[13] Ma J K,Drake P M, Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet, 2003, 4(10): 794-805.
[14] Boehm R. Bioproduction of therapeutic proteins in the 21st century and the plant and plant cells as production platforms. Ann NY Acad Sci, 2007, 1102: 121-134.
[15] Fischer R, Emans N. Molecular farming of pharmaceutical proteins. Transgenic Res, 2000, 9: 279-299.
[16] Streatfield S J, Howard J A. Plant-based vaccines. Int J Parasitol, 2003, 33(5-6): 479-493.
[1] LI Chao, LIU Bo, TAO Yu-fen, LI Xin-tong, LIU Jian-sheng, LIU Hong-qi. Expression of Chimeric Protein of Norovirus P Domain and Neutralizing Epitopes of EV71 in Prokaryotic Escherichia coli[J]. China Biotechnology, 2017, 37(1): 1-6.
[2] ZHANG Ji-Wen, YANG Gui-Lian, WANG Chun-Feng. The Use of Retroviral Vector in Genetically Engineering Vaccine[J]. China Biotechnology, 2010, 30(06): 130-133.
[3] ZHANG Hai-Yan, YANG Hong-Jun, WANG Chang-Fa, HE Hong-Ban, ZHONG Ji-Feng, YANG Shao-Hua, MA Wei-Meng. Evaluation of the Immunity Effectiveness on the Engineered Subunit Vaccine of Staphylococcus aureus α-Hemolysin[J]. China Biotechnology, 2009, 29(11): 17-22.